Therefore, NAT2 SNP-inferred slow acetylation status potentially measured variations in both N- and O-acetylation catalytic capacities [28], and was associated with decreased risk of bladder cancer in our study. The gene discussed is NAT2; the disease is urinary bladder cancer.